AKL Research and Development
APPA Unmet Need
>30 million
The number of US residents with OA in 2016 is estimated at over 30 million
Over 2%
The burden to society of OA in developed counties is in excess of 2% annual GDP
OA limits life
Increased risk of cardiovascular disease, diabetes, hypertension and early death
FDA has recently classed OA ‘a serious disease’
Activity limitations 80% – increased risk of early death. Current therapies have small effect, costly and associated with life threatening adverse events.
Osteoarthritis is a chronic, painful, degenerative, progressive arthropathy that is one of the leading causes of pain and disability worldwide. It affects ~10% global population >60-years old ( Pereira 2011).
After many years of research to identify new anti-inflammatory drugs, corticosteroids and NSAIDs (non-steroidal anti-inflammatory drugs) are still the main agents used to control inflammation. Many patients rotate through several of these due to insufficient efficacy, adverse side effects and/or use unproven complementary therapies.
A significant unmet medical need continues to exist for pain relief associated with OA.
For more information on OA, please visit Versus Arthritis.